Skip to content

Discovering Medicines that Target Inflammation at its Core

Quench Bio is leveraging new
understandings in the molecular biology
of inflammation to create novel
medicines that treat patients with severe
inflammatory diseases.

Quench Bio is leveraging new
understandings in the molecular biology
of inflammation to create novel
medicines that treat patients with severe
inflammatory diseases.

Our Core Focus: Gasdermin

At Quench Bio we are discovering inhibitors of novel targets in innate immunity, the gasdermins. A central player in multiple pathways leading to inflammatory cell death, Gasdermin D acts as the executioner of pyroptosis and NETosis. By targeting this core node in innate immunity, we will inhibit multiple inflammatory pathways simultaneously, potentially creating a transformational therapy for patients with severe inflammatory diseases.

Right Team, Right Time

Quench Bio has assembled an experienced team consisting of both veteran biopharma leaders as well as scientists with deep expertise in inflammation and gasdermin biology. Guided by world-class scientific advisors and supported by a seasoned board of directors, we are well-positioned to realize the potential of gasdermins as meaningful therapeutic targets and bring new, impactful therapies to patients.